Shots: The sNDA follows clinical, non-clinical, chemistry, manufacturing and controls (CMC) data and P-II study results assessing Tislelizumab in 113 patients with LA or metastatic UC prior treated with PD-L1+ […]readmore
Tags : Urothelial Carcinoma
Shots: The approval is based on P-II (BLC2001, NCT02365597) study results assessing 87 patients with disease that had progressed on or after at least one prior chemotherapy and that had […]readmore